Want to see SXTP full AI Analyst Report?
SXTP Stock Chart & Stats
$0.50
-$0.08(-5.71%)
At close: 4:00 PM EST
$0.50
-$0.08(-5.71%)
Day’s Range― - ―
52-Week Range$1.22 - $8.62
Previous CloseN/A
Volume13.44M
Average Volume (3M)199.18K
Market Cap
$4.04M
Enterprise Value$9.32
Total Cash (Recent Filing)$3.34M
Total Debt (Recent Filing)$151.97K
Price to Earnings (P/E)―
Beta2.43
Next Earnings
Aug 19, 2026EPS Estimate
-0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.15
Shares Outstanding2,659,288
10 Day Avg. Volume488,900
30 Day Avg. Volume199,179
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.39
Price to Sales (P/S)1.35
P/FCF Ratio-0.19
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.70Price Target Upside640.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.16
Revenue Forecast (FY)$1.30M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Stronger Balance SheetMinimal debt and positive equity (~$4.7M) reduce insolvency risk and give management flexibility to fund development or partner programs without immediate debt stress. A cleaner balance sheet supports strategic options and extends runway relative to heavily levered peers.
Regulatory Path For TafenoquineA formal interim statistical analysis plan and defined decision rules create a credible pathway to a supplementary NDA by Q1 2028 and potential priority review voucher. This structured regulatory strategy, if successful, materially improves upside and shortens time-to-market for tafenoquine.
Pipeline Diversification Via IP OptionThe exclusive option on castanospermine IP expands the company beyond malaria and babesiosis into multiple tick-borne diseases, increasing addressable markets and long-term value potential. Broader indications can attract partners and reduce reliance on a single program.
Bears Say
High Cash BurnSustained and worsening negative operating and free cash flow (~-$8.2M TTM) rapidly depletes liquidity and forces recurring external financing. This structurally increases dilution risk, constrains R&D continuity, and raises the probability of funding-driven program delays absent material revenues or deals.
Tiny, Declining Revenue BaseA very small and shrinking revenue base (~$1M, -14.5% YoY) versus large net losses (~$7.6M) shows the cost base far exceeds current commercial scale. Without successful approvals or commercial expansion, ongoing negative margins will persist and erode equity, limiting self-funded growth prospects.
Binary Clinical / Regulatory DependenceThe company’s strategic value hinges on positive tafenoquine trial outcomes and regulatory approval; these binary events determine ability to commercialize and obtain a priority review voucher. Such dependency prolongs cash burn exposure and makes long-term prospects highly outcome-sensitive.
60 Degrees Pharmaceuticals, Inc. News
SXTP FAQ
What was 60 Degrees Pharmaceuticals, Inc.’s price range in the past 12 months?
60 Degrees Pharmaceuticals, Inc. lowest stock price was $1.22 and its highest was $8.62 in the past 12 months.
What is 60 Degrees Pharmaceuticals, Inc.’s market cap?
60 Degrees Pharmaceuticals, Inc.’s market cap is $4.04M.
When is 60 Degrees Pharmaceuticals, Inc.’s upcoming earnings report date?
60 Degrees Pharmaceuticals, Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 32 days.
How were 60 Degrees Pharmaceuticals, Inc.’s earnings last quarter?
Currently, no data Available
Is 60 Degrees Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts 60 Degrees Pharmaceuticals, Inc.’s price is currently Undervalued.
Does 60 Degrees Pharmaceuticals, Inc. pay dividends?
60 Degrees Pharmaceuticals, Inc. does not currently pay dividends.
What is 60 Degrees Pharmaceuticals, Inc.’s EPS estimate?
60 Degrees Pharmaceuticals, Inc.’s EPS estimate is -0.74.
How many shares outstanding does 60 Degrees Pharmaceuticals, Inc. have?
60 Degrees Pharmaceuticals, Inc. has 2,659,288 shares outstanding.
What happened to 60 Degrees Pharmaceuticals, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of 60 Degrees Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in SXTP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is undergoing Phase IIb clinical trials for potential use against COVID-19. Additionally, Tafenoquine is the subject of Phase IIA clinical studies for conditions such as babesiosis, fungal pneumonias, and candidiasis. Another candidate, Celgosivir, is being developed to address Zika, various respiratory viruses, and dengue fever. Further strengthening its development efforts, 60 Degrees Pharmaceuticals holds a patent license agreement with Tufts Medical Center, collaborating to advance Tafenoquine specifically for the treatment and prevention of babesiosis. The company was established in 2010 and maintains its corporate headquarters in Washington, D.C.
SXTP Stock 12 Month Forecast
Average Price Target
$3.70
▲(640.00% Upside)
Technical Analysis
Ownership Overview
1.08% Insiders
0.33% Mutual Funds
5.44% Other Institutional Investors
93.15% Public Companies and
Individual Investors